It could bring more competition, but not enough to change our valuations.
We're maintaining Walgreens' narrow moat rating and $42 fair value estimate.
Stabilizing pricing and improved efficiencies should lead to steady gains and needed debt repayments for the generic drugmakers.
Teva's shares have declined nearly 70% from the 52-week high with the rise of opioid litigation.
The wide-moat company is expanding outside life sciences for even more growth.
It continues to inflict pain on drug manufacturers and distributors.
We maintain our no-moat rating and await additional details on the Pfizer transaction.
We think the pharmacy retailer can further leverage its significant scale.
All three companies still trade at 4 stars, however.